A Phase II Study of Fludarabine (F), Rituximab and Avastin (A) Followed by RA Maintenance Therapy in Patients With Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL).

Trial Profile

A Phase II Study of Fludarabine (F), Rituximab and Avastin (A) Followed by RA Maintenance Therapy in Patients With Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL).

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Fludarabine (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 26 Jul 2010 Planned end date changed from 1 Mar 2014 to 1 Sep 2017 as reported by ClinicalTrials.gov.
    • 26 Jul 2010 Actual initiation date changed from Sep 2009 to Jan 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top